Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and increased the price target from $37 to $38.
May 09, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Mirum Pharmaceuticals and raised its price target from $37 to $38.
The increase in price target by a reputable analyst like David Lebovitz at Citigroup typically signals a positive outlook on the stock, suggesting a strong belief in the company's future performance. This can often lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100